The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC).
Julie E. Bauman
Research Funding - Genentech
Neil D. Gross
Research Funding - Astellas Pharma
William E. Gooding
No relevant relationships to disclose
William Denq
No relevant relationships to disclose
Sufi M. Thomas
No relevant relationships to disclose
Lin Wang
No relevant relationships to disclose
Simion I. Chiosea
No relevant relationships to disclose
Brian L Hood
No relevant relationships to disclose
Melanie S Flint
No relevant relationships to disclose
Mai Sun
No relevant relationships to disclose
Thomas P. Conrads
No relevant relationships to disclose
Robert L. Ferris
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb; VentiRx
Jonas Talmadge Johnson
No relevant relationships to disclose
Seungwon Kim
No relevant relationships to disclose
Athanassios Argiris
Research Funding - Genentech
Lori J. Wirth
No relevant relationships to disclose
Jill Siegfried
No relevant relationships to disclose
Jennifer R. Grandis
Research Funding - Bristol-Myers Squibb; Novartis; OSI Pharmaceuticals